Advancing Precision Nutrition: Wearable Technology for Noninvasive Insulin Monitoring
Texas A&M University · NCT07254364
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–90 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 32
- US sites recruiting
- 1
- Study start
- September 11, 2025
- Record last updated
- October 5, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Noninvasively monitoring insulin is crucial for advancing precision nutrition and promoting healthy living by enabling a deeper understanding of individual metabolic responses to dietary intake. Insulin is a key regulator of blood sugar and energy metabolism, and its dysregulation is linked to conditions such as diabetes, obesity, and metabolic syndrome. By noninvasively tracking insulin levels, individuals can gain real-time insights into how their body processes different foods, allowing for the personalization of diets to optimize metabolic health, manage weight, and reduce disease risk. This approach also empowers proactive lifestyle adjustments to maintain insulin sensitivity, improve glycemic control, and enhance overall well-being. Decentralized insulin quantification in biofluids, including saliva and serum, based on lateral flow assay or electrochemical sensor has been reported. However, these approaches have poor sensitivity and fail to quantify insulin with a high temporal resolution.
Being studied: Standardized meal 1
Conditions: Insulin Response; Type 1 Diabetes
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion criteria
- Age
- ● 18-30 years old
- ● 50-90 years old
- BMI between 18 and 35 kg/m2
- Ability to walk, sit down, and stand up (independently or with a walking assistance device)
- Willingness to lay supine in bed for up to 9 hours
- Willingness and ability to comply with the protocol
Exclusion criteria
- Known allergy to any of the components of the meal or agents used for the application of the devices
- Sunflower oil
- Maltodextrin
- Whey protein
- Pilocarpine solutions
- Established diagnosis and active treatment of chronic disease: insulin-dependent diabetes, active malignancy, heart failure, kidney disease, liver disease, HIV/AIDS, asthma (moderate to severe), Hep (A, B, or C)
- History of untreated metabolic disease including hepatic or renal disorder
- Presence of acute illness or metabolically unstable chronic illness
- Active dependence on alcohol or drugs
- Use of a short course of oral corticosteroids within 4 weeks preceding study day
- Current use of long-term oral corticosteroids
- Presence of fever within the last 3 days
- Planned elective surgery requiring 2 or more days of hospitalization during the entire study
- (Possible) pregnancy (confirmed via urine pregnancy test for females 18-30 years)
- Failure to give informed consent or Investigator's uncertainty about the willingness or ability of the subject
- Any condition according to the PI or nurse that was found during the screening visit, that would interfere with the study or safety of the patient
Recruiting US locations
Texas A&M University
College Station, TX 77843
Site contact: Nicolaas Deutz
Study contacts (from the official record)
- Nicolaas Deutz · 979-458-1484 · nep.deutz@ctral.org
- Laura Ruebush · 979-458-1484 · le.ruebush@ctral.org
Similar studies in Texas
All diabetes studies in Texas →- RecruitingHealthy volunteersPhase 1
Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)
Gilead Sciences
- Location
- San Antonio, TX + 2 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteersPhase 1
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of…
AstraZeneca
- Location
- San Antonio, TX + 3 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingHealthy volunteersPhase 1
Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)
Ocugen
- Location
- Bellaire, TX + 4 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 1Overnight stay mentioned
MAD Study to Assess the Safety, Tolerability, PKs and Efficacy of YJ001 for Spray Use in Patients With DPNP
Zhejiang Hanmai Pharmaceutical Technology Co., Ltd.
- Location
- Fredericksburg, TX
- Eligibility basics
- Ages 18–80